Growth retardation of children after renal transplant surgery is effective with recombinant human growth hormone (rhGH) treatment. However, due to the potential immune regulation of growth hormone, its safety is still controversial.
Recently, German scholar has studied the changes of helper T lymphocyte (TH) immunophenotype after treatment with rhGH in pediatric patients after renal transplantation. They studied 13 children (Tx + GH) treated with rhGH after renal transplantation, 11 had preoperative chronic renal failure, and treated with rhGH in children (CRF + GH) and 33 patients with renal transplantation (Tx group) was used as a control to measure the cytokines, activating markers, stimuli and adhesion molecules in each group. Flow cytometry was used to evaluate the effect of rhGH on the expression of rhGH 12, 18 and 24 weeks respectively.
The results showed that there was no significant difference between Tx + GH group and Tx group before treatment. The levels of interleukin-2 (IL-2) in the Tx + GH group were three times higher than those in the control group at the fourth week after rhGH treatment, and 70% for IL-4 and IL-13 at 12 weeks. All three cytokines were returned to baseline at week 18. And did not find a rejection reaction. The baseline levels of all three cytokines in the CRF + GH group were higher than those in the kidney transplant recipients, but were not affected by rhGH therapy.
The author believes that rhGH treatment of patients with stable renal transplant patients, will produce a certain degree of transient immune stimulation, so the use of rhGH treatment should be closely tested immunosuppressive state and transplant function.
Beijing In China